Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joel Fishbein is active.

Publication


Featured researches published by Joel Fishbein.


Oncologist | 2016

A Systematic Review of Adherence to Oral Antineoplastic Therapies

Joseph A. Greer; Nicole Amoyal; Lauren Nisotel; Joel Fishbein; James MacDonald; Jamie M. Stagl; Inga T. Lennes; Jennifer S. Temel; Steven A. Safren; William F. Pirl

BACKGROUND Oral antineoplastic therapies not only improve survival but also reduce the burden of care for patients. Yet patients and clinicians face new challenges in managing adherence to these oral therapies. We conducted a systematic literature review to assess rates and correlates of adherence to oral antineoplastic therapies and interventions aimed at improving adherence. METHODS Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a comprehensive literature search of the Ovid MEDLINE database from January 1, 2003 to June 30, 2015, using relevant terminology for oral antineoplastic agents. We included observational, database, and intervention studies. At least two researchers evaluated each paper to ensure accuracy of results and determine risk of bias. RESULTS We identified 927 records from the search and screened 214 abstracts. After conducting a full-text review of 167 papers, we included in the final sample 51 papers on rates/correlates of adherence to oral antineoplastic therapy and 12 papers on intervention studies to improve adherence. Rates of adherence varied widely, from 46% to 100%, depending on patient sample, medication type, follow-up period, assessment measure, and calculation of adherence. Of the intervention studies, only 1 of the randomized trials and 2 of the cohort studies showed benefit regarding adherence, with the majority suffering high risk of bias. CONCLUSIONS Although no reliable estimate of adherence to oral antineoplastic therapies can be gleaned from the literature, a substantial proportion of patients struggle to adhere to these medications as prescribed. The few intervention studies for adherence have notable methodological concerns, thereby limiting the evidence to guide practice in promoting medication adherence among patients with cancer.


Cancer | 2016

The relationship between coping strategies, quality of life, and mood in patients with incurable cancer.

Ryan D. Nipp; Areej El-Jawahri; Joel Fishbein; Justin Eusebio; Jamie M. Stagl; Emily R. Gallagher; Elyse R. Park; Vicki A. Jackson; William F. Pirl; Joseph A. Greer; Jennifer S. Temel

Patients with incurable cancer face many physical and emotional stressors, yet little is known about their coping strategies or the relationship between their coping strategies, quality of life (QOL), and mood.


JMIR Research Protocols | 2017

Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and Development

Joel Fishbein; Lauren Nisotel; James MacDonald; Nicole Amoyal Pensak; Jamie M. Jacobs; Clare Flanagan; Kamal Jethwani; Joseph A. Greer

Background Oral chemotherapy is increasingly used in place of traditional intravenous chemotherapy to treat patients with cancer. While oral chemotherapy includes benefits such as ease of administration, convenience, and minimization of invasive infusions, patients receive less oversight, support, and symptom monitoring from clinicians. Additionally, adherence is a well-documented challenge for patients with cancer prescribed oral chemotherapy regimens. With the ever-growing presence of smartphones and potential for efficacious behavioral intervention technology, we created a mobile health intervention for medication and symptom management. Objective The objective of this study was to develop and evaluate the usability and acceptability of a smartphone app to support adherence to oral chemotherapy and symptom management in patients with cancer. Methods We used a 5-step development model to create a comprehensive mobile app with theoretically informed content. The research and technical development team worked together to develop and iteratively test the app. In addition to the research team, key stakeholders including patients and family members, oncology clinicians, health care representatives, and practice administrators contributed to the content refinement of the intervention. Patient and family members also participated in alpha and beta testing of the final prototype to assess usability and acceptability before we began the randomized controlled trial. Results We incorporated app components based on the stakeholder feedback we received in focus groups and alpha and beta testing. App components included medication reminders, self-reporting of medication adherence and symptoms, an education library including nutritional information, Fitbit integration, social networking resources, and individually tailored symptom management feedback. We are conducting a randomized controlled trial to determine the effectiveness of the app in improving adherence to oral chemotherapy, quality of life, and burden of symptoms and side effects. At every stage in this trial, we are engaging stakeholders to solicit feedback on our progress and next steps. Conclusions To our knowledge, we are the first to describe the development of an app designed for people taking oral chemotherapy. The app addresses many concerns with oral chemotherapy, such as medication adherence and symptom management. Soliciting feedback from stakeholders with broad perspectives and expertise ensured that the app was acceptable and potentially beneficial for patients, caregivers, and clinicians. In our development process, we instantiated 7 of the 8 best practices proposed in a recent review of mobile health app development. Our process demonstrated the importance of effective communication between research groups and technical teams, as well as meticulous planning of technical specifications before development begins. Future efforts should consider incorporating other proven strategies in software, such as gamification, to bolster the impact of mobile health apps. Forthcoming results from our randomized controlled trial will provide key data on the effectiveness of this app in improving medication adherence and symptom management. Trial Registration ClinicalTrials.gov NCT02157519; https://clinicaltrials.gov/ct2/show/NCT02157519 (Archived by WebCite at http://www.webcitation.org/6prj3xfKA)


Journal of Clinical Oncology | 2016

Effect of early integrated palliative care on family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer.

Areej El-Jawahri; Vicki A. Jackson; Joseph A. Greer; William F. Pirl; Elyse R. Park; Anthony L. Back; Alona Muzikansky; Mihir M. Kamdar; Simone Rinaldi; Juliet Jacobsen; Joel Fishbein; Justin Eusebio; Harry VanDusen; Ryan D. Nipp; David P. Ryan; Jennifer S. Temel

234 Background: Patients with newly diagnosed advanced cancers who receive early palliative care (PC) integrated with oncology care report improvement in their quality of life (QOL) and mood. While a telephone-based psycho-educational intervention for FC decrease depression, the impact of early, integrated outpatient PC models on FC outcomes remains unknown. METHODS We conducted a randomized trial of early PC integrated with oncology care versus oncology care alone for newly diagnosed patients with incurable lung and gastrointestinal cancers and their FC. Eligible FC were relatives or friends who would likely accompany the patient to clinic visits. FC were eligible to enroll up to 4 weeks after patient enrollment. The intervention entailed at least monthly patient visits with PC from the time of enrollment. FC were not required to attend these visits. We used the Medical Outcomes Study Health Survey Short Form-36 to examine QOL and the Hospital Anxiety and Depression Scale to examine mood at baseline, weeks 12 and 24. We used the two-sample t-test to examine changes in QOL and mood from baseline to week 12 and week 24. RESULTS We enrolled 350 patients and 275 (78.6%) of potentially eligible FC (control n = 138, intervention n = 137) between 5/2/2011 to 7/20/2015. FC outcomes missing data rate at 12 and 24 weeks were 16.8% and 33.8% respectively. At 12 weeks, FC of patients receiving early PC reported higher vitality (1.1 vs. -3.2, p = 0.05) and social functioning (-3.0 vs. -3.8, p = 0.02), and lower depression symptoms (-0.45 vs. 0.24, p = 0.03) compared to FC of patients assigned to usual care. At 24 weeks, FC of patients assigned to early PC had lower depression symptoms (-0.37 vs. 0.28, p = 0.05), but no differences in vitality or social functioning compared to those receiving usual care. No differences in other SF-36 subscales or anxiety were noted at 12 and 24 weeks. CONCLUSIONS Early involvement of PC for patients with newly diagnosed lung and gastrointestinal cancers leads to improvements in FC depression and aspects of QOL. This work demonstrates that the benefits of early, integrated palliative care models in oncology care extend beyond patient outcomes and positively impact the experience of FC. CLINICAL TRIAL INFORMATION NCT01401907.


Journal of Clinical Oncology | 2015

Qualitative study of patients’ and family caregivers’ (FC) perceptions and information preferences about hospice.

Areej El-Jawahri; Jennifer A. Shin; Lara Traeger; Helen Knight; Kristina Mirabeau-Beale; Joel Fishbein; Harry VanDusen; Tanya Keenan; Vicki A. Jackson; Angelo E. Volandes; Jennifer S. Temel

50 Background: Despite the benefits of hospice for patients with advanced cancer and their FC, many patients are referred late or not at all. To assess potential patient and FC barriers to enrollment, we assessed their perceptions, knowledge, and information preferences about hospice. METHODS We conducted qualitative interviews with 16 adult patients with metastatic cancer and a prognosis ≤ 12 months and 8 of their FC. We used a semi-structured interview guide to elicit their perceptions (including perceived barriers to utilization), knowledge, and information preferences about hospice. Two raters coded interviews independently and reached acceptable inter-rater reliability (κ > 0.85). We used content analysis to identify themes. RESULTS We found similar themes between patients and FC interviews. Participants had mixed views about which patients need hospice with some stating it is for patients only at the end-of-life and others perceiving it as important for patients who need care their family cannot provide. Notably, most patients perceived themselves as not needing hospice in the near future. While the majority perceived the role of hospice to enhance quality of life and provide comfort, some viewed it as providing practical support, including 24-hour care. 50% of participants had positive feelings about hospice, while others were more ambivalent. All participants felt they needed more information about hospice, yet they were mixed regarding the optimal timing of this information. Many thought it would be helpful to have information about hospice through pamphlets, websites, or videos, prior to a discussion with their oncologist. Most viewed denial and hope as the main barriers to early hospice enrollment. CONCLUSIONS Study participants had misunderstandings about which patients were appropriate for hospice and regarding the services offered. Participants expressed strong desires for more information about hospice with educational tools, although were mixed about the optimal timing for reviewing these tools. These findings suggest that patients and FC would benefit from interventions to enhance their understanding of hospice and to facilitate a discussion with their oncologists.


Cancer | 2016

Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation.

Areej El-Jawahri; Harry VanDusen; Lara Traeger; Joel Fishbein; Tanya Keenan; Emily R. Gallagher; Joseph A. Greer; William F. Pirl; Vicki A. Jackson; Thomas R. Spitzer; Yi-Bin Chen; Jennifer S. Temel


Annals of Oncology | 2016

Factors associated with depression and anxiety symptoms in family caregivers of patients with incurable cancer

Ryan D. Nipp; Areej El-Jawahri; Joel Fishbein; Emily R. Gallagher; Jamie M. Stagl; Elyse R. Park; Vicki A. Jackson; William F. Pirl; Joseph A. Greer; Jennifer S. Temel


Journal of Pain and Symptom Management | 2017

Coping in Patients With Incurable Lung and Gastrointestinal Cancers: A Validation Study of the Brief COPE

Teresa L. Hagan; Joel Fishbein; Ryan D. Nipp; Jamie M. Jacobs; Lara Traeger; Kelly E. Irwin; William F. Pirl; Joseph A. Greer; Elyse R. Park; Vicki A. Jackson; Jennifer S. Temel


Annals of Behavioral Medicine | 2017

Distress is Interdependent in Patients and Caregivers with Newly Diagnosed Incurable Cancers

Jamie M. Jacobs; Kelly M. Shaffer; Ryan D. Nipp; Joel Fishbein; James MacDonald; Areej El-Jawahri; William F. Pirl; Vicki A. Jackson; Elyse R. Park; Jennifer S. Temel; Joseph A. Greer


Journal of Memory and Language | 2014

Making sense of Kafka: Structural biases induce early sense commitment for metonyms

Joel Fishbein; Jesse A. Harris

Collaboration


Dive into the Joel Fishbein's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge